tradingkey.logo
tradingkey.logo
Search

Acumen Pharmaceuticals Inc

ABOS
Add to Watchlist
2.740USD
+0.150+5.79%
Close 07/02, 13:00ETQuotes delayed by 15 min
197.90MMarket Cap
LossP/E TTM

TradingKey Stock Score of Acumen Pharmaceuticals Inc

Currency: USD Updated: 2026-07-02

Key Insights

Acumen Pharmaceuticals Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 112 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 7.20.In the medium term, the stock price is expected to remain stable.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Acumen Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
112 / 387
Overall Ranking
235 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Acumen Pharmaceuticals Inc Highlights

StrengthsRisks
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The Company is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -1.48, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 45.02M shares, increasing 1.51% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 62.60K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.75.

Analyst Rating

Based on 6 analysts
Strong Buy
Current Rating
7.200
Target Price
+177.99%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Acumen Pharmaceuticals Inc?

The TradingKey Stock Score provides a comprehensive assessment of Acumen Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Acumen Pharmaceuticals Inc’s performance and outlook.

How do we generate the financial health score of Acumen Pharmaceuticals Inc?

To generate the financial health score of Acumen Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Acumen Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Acumen Pharmaceuticals Inc.

How do we generate the company valuation score of Acumen Pharmaceuticals Inc?

To generate the company valuation score of Acumen Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Acumen Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Acumen Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Acumen Pharmaceuticals Inc.

How do we generate the earnings forecast score of Acumen Pharmaceuticals Inc?

To calculate the earnings forecast score of Acumen Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Acumen Pharmaceuticals Inc’s future.

How do we generate the price momentum score of Acumen Pharmaceuticals Inc?

When generating the price momentum score for Acumen Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Acumen Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for Acumen Pharmaceuticals Inc.

How do we generate the institutional confidence score of Acumen Pharmaceuticals Inc?

To generate the institutional confidence score of Acumen Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Acumen Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Acumen Pharmaceuticals Inc.

How do we generate the risk management score of Acumen Pharmaceuticals Inc?

To assess the risk management score of Acumen Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Acumen Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Acumen Pharmaceuticals Inc.